<DOC>
	<DOCNO>NCT00007982</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplant may allow doctor give high dos chemotherapy drug kill cancer cell . PURPOSE : This phase II trial study well chemotherapy peripheral stem cell transplant work treat patient central nervous system cancer .</brief_summary>
	<brief_title>Chemotherapy Plus Peripheral Stem Cell Transplant Treating Patients With Central Nervous System Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine response rate patient central nervous system malignancy treat intensive chemotherapy support autologous peripheral blood stem cell transplantation follow surgical resection and/or radiotherapy . - Determine disease-free survival overall survival patient population treat regimen . - Determine toxicity high-dose chemotherapy regimen patient . - Assess quality life patient follow treatment regimen . OUTLINE : Patients anaplastic astrocytoma , esthesioneuroblastoma , germ cell tumor , primary neuroectodermal tumor undergo initial surgical resection follow conventional stereotactic radiotherapy . Patients germ cell primary neuroectodermal tumor also receive 4 course standard chemotherapy comprise cyclophosphamide , etoposide , cisplatin prior high-dose chemotherapy . All patient undergo peripheral blood stem cell bone marrow harvest follow high-dose chemotherapy consolidation . Patients receive thiotepa IV 3 time daily day -7 -3 , carmustine IV 1 hour day -6 -3 , etoposide IV 5 hour day -6 -3 . Patients undergo transplantation day 0 . Filgrastim ( G-CSF ) administer concurrently stem cell harvest transplantation . Patients recurrent oligodendroglioma CNS lymphoma receive radiotherapy diagnosis undergo conventional radiotherapy 6 week completion high-dose chemotherapy . Patients follow every 2-3 month 1 year annually 5 year . Quality life assess follow-up . PROJECTED ACCRUAL : A total 30 patient accrue study 3 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm malignant tumor Anaplastic astrocytoma Oligodendroglioma Germ cell tumor Medulloblastoma Primary neuroectodermal tumor Esthesioneuroblastoma CNS lymphoma ( primary systemic disease ) Multifocal intracranial disease allow No extraneural metastasis ( except control systemic lymphoma ) Pretreatment consideration base tumor type Anaplastic astrocytoma : Recurrent disease Any treatment diagnosis allow ( carmustine dose limit 480 mg/m2 ) Chemotherapy require recurrence Oligodendroglioma : Disease response ( least minor ) conventional chemotherapy OR Recurrent disease Esthesioneuroblastoma : Attempted complete surgical resection Disease progression radiotherapy Response chemotherapy regimen comprise cyclophosphamide , etoposide , cisplatin CNS lymphoma : Disease refractory methotrexate OR Failure initial treatment methotrexate OR Considered high risk disease relapse despite initial response Radiographic pathological confirmation recurrent disease require Not eligible high priority national institutional clinical study PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG Zubrod 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Creatinine le 1.5 time normal Cardiovascular : LVEF least 45 % Pulmonary : DLCO least 60 % predict OR Approval pulmonologist Other : Not pregnant nursing HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : No concurrent anticancer hormonal therapy No concurrent steroid antiemetic Radiotherapy : See Disease Characteristics Surgery : See Disease Characteristics Other : No concurrent barbiturates acetaminophen Participation concurrent supportive care gene therapy trial allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult medulloblastoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult central nervous system germ cell tumor</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
</DOC>